PDCD1 and neoplasm: These include the presence of PD-1 positive T cells and the expression of its ligand, programmed cell death-1 ligand-1 (PD-L1), in the tumor microenvironment (TME), as well as a high tumor mutation burden harboring immunogenic neoantigens [5,6,7,8].